Journal
MOLECULAR ASPECTS OF MEDICINE
Volume 58, Issue -, Pages 44-56Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.mam.2017.04.003
Keywords
Lipoxins; Resolvins; Protectins; Maresins; Catabasis; Efferocytosis; Lung; Leukocytes; Airway; Mucosa
Funding
- National Institutes of Health [R01-HL122531, U01-HL108712, U10-HL109172, U24-AI118656, P01-GM095467, K12-HD047349]
- Sao Paulo Research Foundation (FAPESP) [2015/26048-5]
- Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [15/26048-5] Funding Source: FAPESP
Ask authors/readers for more resources
Bronchi are exposed daily to irritants, microbes and allergens as well as extremes of temperature and acid. The airway mucosal epithelium plays a pivotal role as a sentinel, releasing alarmins when danger is encountered. To maintain homeostasis, an elaborate counter-regulatory network of signals and cellular effector mechanisms are needed. Specialized pro-resolving mediators (SPMs) are chemical mediators that enact resolution programs in response to injury, infection or allergy. SPMs are enzymatically derived from essential polyunsaturated fatty acids with potent cell-type specific immunoresolvent properties. SPMs signal by engaging cell-based receptors to turn off acute inflammatory responses and restore tissue homeostasis. Several common lung diseases involving the airways, including asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis (CF), are characterized by unresolved bronchial inflammation. In preclinical murine models of lung disease, SPMs carry potent bronchoprotective actions. Here, we review cellular and molecular effects for SPM-initiated catabasis in the lung and their human translation. (C) 2017 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available